References
- YARDEN Y, ULLRICH A: Growth Factor Re-ceptor Tyrosine Kinases. Ann. Rev. Biochem. (1988) 57:443–478.
- ULLRICH A, SCHLESSINGER J: Signal trans-duction by receptors with tyrosine kinase ac-tivity. Cell (1990) 61:203–212.
- PAWSON T: Tyrosine kinases and their inter-actions with signalling proteins. Curr. Opin. Gen. Dev. (1992) 2:4–12.
- COOPER JA: The src-family of protein tyro-sine kinases. In: Peptides and protein phos-phorylation (1990) Kemp B, Alewood P (Eds). CRC Press, Boca Raton, Florida, pp85–113.
- HUNTER T: Oncogene products in the cyto-plasm: The protein kinases. In: Oncogenes and the molecular origins of cancer. Weinberg RA (Ed) Cold Spring Harbor Press.
- CLARK SS, CRIST WM, W11-il. ON: Molecular pathogenesis of Ph-positive leukemias. Annu. Rev. Med. (1989) 40:113–122.
- PAGE MJ, CROMPTON M, AFFLECK K, SPENCE P: Potential of tyrosine idnase receptors as therapeutic targets in cancer. In: Cancer in the 21st Century. Huber B (Ed). In Press.
- LB3ERMANN TA, NUSBAUM HR, RAZON N, lats R, LAX I, SOREQ H, WHITTLE N, WATERF1ELD MD, ULLRICH A, SCHLESSINGER J: Amplification and enhanced expression and possible rearrangement of EGF recep-tor gene in primary human brain tumours of glial origin. Nature (1985) 313:144–147.
- SAINSBURY JRC, FARNDON JR, NEEDHAM GK, MALCOLM AJ, HARRIS AL: Epidermal growth factor receptor status as a predictor of early recurrence of and death from breast cancer. Lancet (1987) 1:1398–1402.
- SLAMON DJ, GODOPHIN W, JONES LA, HOLT JA, WONG SG, KEITH DE, LEVIN WJ, STUART SG, UDOVE J, ULLRICH A, PRESS MJ: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244:707–712.
- LEvram A: Tyrphostins-potential antipro-liferative agents and novel molecular tools. Biochem. Pharmacol. (1990) 40:913–918.
- MENDELSOHN J: The epidermal growth fac-tor receptor as a target for therapy with antireceptor monoclonal antibodies. Semin. Cancer Biol. (1990) 1:339–344.
- DREBIN JA, LINK VC, STERN DF, WEINBERG RA, GREENE MI: Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell (1985) 41:695–706.
- DREBIN JA, LINK VC, GREENE MI: Mono-clonal antibodies specific for the neu onco-gene product directly mediate anti-tumor ef-fects in vivo. Oncogene (1988) 2:387–394.
- PLOWMAN D, WHITNEY GS, NEUBAUER MG, GREEN JM, MCDONALD VL, TODARO GJ, SHOYAB M: Molecular cloning and expres-sion of an additional epidermal growth fac-tor receptor-related gene. Proc. NatL Acad. Sci. USA (1990) 87:4905–4909.
- YARDEN Y, WEINBERG RA: Experimental ap-proaches to hypothetical hormones: Detec-tion of a candidate ligand of the neu pro-tooncogene. Proc. NatL Acad. Sci. USA (1989) 86:3179–3183.
- LUPU R, COLOMEER R, ZUGMAIER G, SARUP J, SHEPARD M, SLAMON D, LIPPMAN ME: Direct interaction of a figand for the erbB2 onco-gene product with the EGF receptor and p185erbB2. Science (1990) 249:1552–1555.
- HOLMES WE, SLIWKOWSKI MX, AKITA RW, HENZEL WJ, LEE J, PARK JW, YANSURA D, ABADI N, RAAB H, LEWIS GD, SHEPARD M, KUANG W-J, WOOD WI, GOEDDEL DV, VANDLEN RL: Identification of Heregulin, a specific activator of p185erbB2. Science (1992) 256:1205–1210.
- MILLER PS: Oligonucleotide methylphospho-nates as antisense reagents. Bio/Technology (1991) 9:358–362.
- CALABRETTA B: Inhibition of protoonco-gene expression by antisense oligodeoxynu-cleotides: biological and therapeutic implica-tions. Can. Res. (1991) 51:4505–4510.
- GUTIERREZ AA, LEMOINE NR, SIKORA K: Gene therapies for cancer. Lancet (1992) 339:715–721.